GPR26

Summary

GPR26 (G protein-coupled receptor 26, HGNC:4481) is a protein-coding gene on chromosome 10q26.13, encoding G-protein coupled receptor 26 (Q8NDV2). Orphan receptor.

This gene encodes a G protein-couple receptor protein. G-protein-coupled receptors are a large family of membrane proteins that are involved in cellular responses to environmental stimuli, neurotransmitters, and hormones. The encoded protein may play a role in neurodegenerative diseases. Epigenetic silencing of this gene has been observed in gliomas.

Source: NCBI Gene 2849 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 43 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_153442

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4481
Approved symbol	GPR26
Name	G protein-coupled receptor 26
Location	10q26.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000154478
Ensembl biotype	protein_coding
OMIM	604847
Entrez	2849

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000284674

RefSeq mRNA: 1 — MANE Select: NM_153442 NM_153442

CCDS: CCDS7636

Canonical transcript exons

ENST00000284674 — 3 exons

Exon	Start	End
ENSE00001016136	123674818	123674931
ENSE00001099658	123666355	123667075
ENSE00001251486	123687929	123697399

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 94.06.

Top tissues by expression

210 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	94.06	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.38	gold quality
substantia nigra pars compacta	UBERON:0001965	92.96	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.92	gold quality
tendon of biceps brachii	UBERON:0008188	92.47	gold quality
middle temporal gyrus	UBERON:0002771	91.97	gold quality
Brodmann (1909) area 46	UBERON:0006483	90.81	gold quality
buccal mucosa cell	CL:0002336	87.87	gold quality
myocardium	UBERON:0002349	86.51	silver quality
left ventricle myocardium	UBERON:0006566	86.17	silver quality
superior frontal gyrus	UBERON:0002661	85.88	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	85.53	silver quality
lateral nuclear group of thalamus	UBERON:0002736	84.68	gold quality
ventral tegmental area	UBERON:0002691	84.33	gold quality
parietal lobe	UBERON:0001872	84.24	gold quality
postcentral gyrus	UBERON:0002581	83.98	gold quality
vena cava	UBERON:0004087	83.96	gold quality
occipital lobe	UBERON:0002021	83.53	gold quality
primary visual cortex	UBERON:0002436	83.48	gold quality
cerebellar vermis	UBERON:0004720	83.09	gold quality
entorhinal cortex	UBERON:0002728	80.99	gold quality
medulla oblongata	UBERON:0001896	80.51	gold quality
pons	UBERON:0000988	79.69	silver quality
lateral globus pallidus	UBERON:0002476	78.93	gold quality
dorsal plus ventral thalamus	UBERON:0001897	78.87	gold quality
superior vestibular nucleus	UBERON:0007227	78.28	gold quality
pharyngeal mucosa	UBERON:0000355	76.79	gold quality
epithelial cell of pancreas	CL:0000083	76.57	gold quality
body of tongue	UBERON:0011876	76.53	gold quality
pancreatic ductal cell	CL:0002079	76.40	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.09

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EZH2

miRNA regulators (miRDB)

349 targeting GPR26, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784

Literature-anchored findings (GeneRIF, showing 4)

• Study has identified GPR26 to be a genetic indicator of primary glioblastoma, suggesting that it could be a suppressor of primary glioblastoma development. (PMID:18037267)
• epigenetic silencing is a common mechanism in malignant gliomas that simultaneously inactivates MGMT and GPR26 (PMID:19787267)
• GPR26 may have a common role in the formation or degradation of intranuclear inclusions in several neurodegenerative diseases (PMID:26303144)
• MiR-188-3p/GPR26 modulation functions as a potential regulator in manipulating glioma cell properties. (PMID:32024457)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpr26	ENSDARG00000074389
mus_musculus	Gpr26	ENSMUSG00000040125
rattus_norvegicus	Gpr26	ENSRNOG00000047057

Paralogs (3): GPR63 (ENSG00000112218), GPR45 (ENSG00000135973), GPR78 (ENSG00000155269)

Protein

Protein identifiers

G-protein coupled receptor 26 — Q8NDV2 (reviewed: Q8NDV2)

All UniProt accessions (1): Q8NDV2

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor. Displays a significant level of constitutive activity. Its effect is mediated by G(s)-alpha protein that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in the CNS, the highest expression is seen in the amygdala, hippocampus and thalamus. Weak expression is detected in testis. Down-regulated in glioblastoma.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_703143* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR049579	GPR26/78-like	Family
IPR051880	GPC_Orphan_Receptors	Family

Pfam: PF00001

UniProt features (22 total): topological domain 8, transmembrane region 7, mutagenesis site 5, chain 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NDV2-F1	90.90	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 79–156

Mutagenesis-validated functional residues (5):

Position	Phenotype
104	no effect on constitutive activity; when associated with e-236.
104	no effect on constitutive activity.
236	no effect on constitutive activity.
236	no effect on constitutive activity; when associated with a-104. no effect on constitutive activity; when associated with

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 75 (showing top): BENPORATH_ES_WITH_H3K27ME3, MODULE_255, MODULE_317, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_ADENYLATE_CYCLASE_ACTIVATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MIKKELSEN_MEF_HCP_WITH_H3K27ME3, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, MIR607, MIR627_3P, MIR4306

GO Biological Process (3): adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (1): G protein-coupled receptor activity (GO:0004930)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

798 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR26	ALDH18A1	P54886	732
GPR26	GAST	P01350	676
GPR26	GPR162	Q16538	653
GPR26	GPR62	Q9BZJ7	582
GPR26	GPR68	Q15743	557
GPR26	GPR101	Q96P66	506
GPR26	FHIP1A	Q05DH4	497
GPR26	GPR82	Q96P67	497
GPR26	GPR31	O00270	494
GPR26	GPR150	Q8NGU9	492
GPR26	GPR20	Q99678	490
GPR26	GPR88	Q9GZN0	475
GPR26	PCP4L1	A6NKN8	470
GPR26	GPR139	Q6DWJ6	455
GPR26	ATP8B2	P98198	454

IntAct

0 interactions, top by confidence:

BioGRID (1): GPR26 (Affinity Capture-Western)

ESM2 similar proteins: A0A287A2K5, F1MV99, O08858, O43193, O77808, O97772, P28646, P30098, P30552, P30553, P30796, P30872, P30873, P30937, P30938, P31391, P32239, P32300, P32307, P32745, P33533, P35346, P35370, P35377, P41143, P41146, P46095, P46627, P47748, P48044, P49660, P51651, P56481, P58406, P79266, P79292, Q49LX5, Q5D0K2, Q6W5G4, Q6YNI2

Diamond homologs: A1ZAX0, B2ZI34, E7EM37, O02664, O54798, O54799, O55197, O62709, O62729, O70342, O97772, O97967, O97969, P17124, P21450, P21451, P21729, P24053, P24530, P25101, P26684, P28088, P28336, P30550, P32247, P32940, P35371, P35463, P47751, P48302, P52500, P56497, P97266, Q15761, Q16581, Q28468, Q29010, Q4V622, Q5KSU9, Q5QD07

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	36
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
154374	GRCh38/hg38 10q26.13-26.3(chr10:121588992-133620674)x1	Pathogenic

SpliceAI

383 predictions. Top by Δscore:

Variant	Effect	Δscore
10:123667072:CCAGG:C	donor_loss	1.0000
10:123667073:CAGG:C	donor_loss	1.0000
10:123667074:AGGTG:A	donor_loss	1.0000
10:123667076:G:A	donor_loss	1.0000
10:123667077:T:A	donor_loss	1.0000
10:123674813:T:G	acceptor_gain	1.0000
10:123674816:AGT:A	acceptor_gain	1.0000
10:123674817:G:GT	acceptor_gain	1.0000
10:123674817:GT:G	acceptor_gain	1.0000
10:123674817:GTG:G	acceptor_gain	1.0000
10:123674817:GTGT:G	acceptor_gain	1.0000
10:123674931:GG:G	donor_loss	1.0000
10:123674933:T:G	donor_loss	1.0000
10:123687928:GGCTA:G	acceptor_gain	1.0000
10:123688149:GTGTC:G	donor_gain	1.0000
10:123688150:TGTCT:T	donor_gain	1.0000
10:123688151:GTCTG:G	donor_gain	1.0000
10:123674810:A:AG	acceptor_gain	0.9900
10:123674811:C:G	acceptor_gain	0.9900
10:123674812:A:AG	acceptor_gain	0.9900
10:123674812:AT:A	acceptor_gain	0.9900
10:123674813:T:TA	acceptor_gain	0.9900
10:123674813:TGCA:T	acceptor_loss	0.9900
10:123674814:GCAGT:G	acceptor_loss	0.9900
10:123674815:CAG:C	acceptor_loss	0.9900
10:123674816:A:AG	acceptor_gain	0.9900
10:123674816:A:AT	acceptor_loss	0.9900
10:123674816:AGTGT:A	acceptor_gain	0.9900
10:123674817:GTGTG:G	acceptor_gain	0.9900
10:123687923:CCACA:C	acceptor_loss	0.9900

AlphaMissense

2162 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:123666693:A:C	S96R	0.997
10:123666695:C:A	S96R	0.997
10:123666695:C:G	S96R	0.997
10:123666708:A:C	S101R	0.997
10:123666710:C:A	S101R	0.997
10:123666710:C:G	S101R	0.997
10:123674892:G:A	G248E	0.997
10:123666548:C:A	N47K	0.996
10:123666548:C:G	N47K	0.996
10:123674897:T:C	F250L	0.996
10:123674899:C:A	F250L	0.996
10:123674899:C:G	F250L	0.996
10:123674916:C:A	P256H	0.995
10:123674916:C:G	P256R	0.995
10:123666945:A:C	S180R	0.994
10:123666947:C:A	S180R	0.994
10:123666947:C:G	S180R	0.994
10:123674906:T:C	C253R	0.993
10:123687999:A:C	S285R	0.993
10:123688001:C:A	S285R	0.993
10:123688001:C:G	S285R	0.993
10:123674891:G:A	G248R	0.992
10:123674891:G:C	G248R	0.992
10:123674909:T:C	F254L	0.992
10:123674911:C:A	F254L	0.992
10:123674911:C:G	F254L	0.992
10:123666476:C:A	N23K	0.991
10:123666476:C:G	N23K	0.991
10:123666538:T:C	F44S	0.991
10:123666550:T:C	L48P	0.991

dbSNP variants (sampled 300 via entrez): RS1000021807 (10:123692125 G>T), RS1000143558 (10:123688639 C>T), RS1000236179 (10:123669764 C>T), RS1000276531 (10:123680986 C>T), RS1000460542 (10:123686104 G>A,T), RS1000534515 (10:123694139 T>C), RS1000540030 (10:123682439 T>A), RS1000729954 (10:123676734 A>G,T), RS1000745755 (10:123687220 G>A), RS1000827151 (10:123669587 C>T), RS1001004350 (10:123688223 G>A), RS1001005894 (10:123675749 A>C), RS1001109793 (10:123669446 C>G), RS1001136300 (10:123695456 G>A), RS1001225203 (10:123679336 T>A)

Disease associations

OMIM: gene MIM:604847 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001776_17	Cardiac Troponin-T levels	9.000000e-06
GCST002759_5	Motion sickness	1.000000e-21
GCST003542_128	Night sleep phenotypes	9.000000e-06
GCST003944_18	Hepcidin/ferritin ratio	2.000000e-06
GCST004904_164	Body mass index	2.000000e-12
GCST004904_233	Body mass index	3.000000e-08
GCST006224_1	Right lateral prefrontal cortical growth	4.000000e-06
GCST007576_234	Chronotype	1.000000e-08
GCST007643_5	Gemcitabine-induced early high-grade neutropenia in pancreatic cancer	4.000000e-06
GCST010988_453	Adult body size	4.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005043	cardiac troponin T measurement
EFO:0006928	motion sickness
EFO:0007901	hepcidin:ferritin ratio
EFO:0004340	body mass index
EFO:0008328	chronotype measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523895 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with no pharmacology

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
kojic acid	decreases expression	1
Acetaminophen	decreases expression	1
Arbutin	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	decreases expression	1
Lead	affects expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883442	Binding	PRESTO-Tango GPCRome screening (GPR26)	Data for DCP probe UCSF924

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KX53	PathHunter CHO-K1 GPR26 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer